



September 22, 2023

✓ **BSE Limited**

Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

We are pleased to enclose a Press Release as regards, the Company having signed an agreement with A. Menarini India Pvt. Ltd. and A. Menarini Asia-Pacific Holdings Pte. Ltd., for acquiring five legacy brands along with the associated trademark rights.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl: a/a.

Lupin Acquires Five Brands from Menarini
Strengthens its Position and Key Therapy Portfolio in India

Mumbai, September 22, 2023: Global pharma major Lupin Limited (Lupin) announced today that it has signed an agreement to acquire five legacy brands in strategic therapy areas - Gastroenterology, Urology and Anti-infectives from Menarini (A. Menarini India Private Limited and A. Menarini Asia-Pacific Holdings Pte. Ltd.), along with the associated trademark rights. The brands are Piclin (Picosulphate Sodium), Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor).

Lupin has been exclusively marketing these brands in the Indian market since July 2021 under a distribution and promotion agreement with A. Menarini India Private Limited. This strategic acquisition for the Indian market marks a significant step forward for Lupin as it continues to expand its presence in India. These legacy brands help Lupin in further enhancing its diverse portfolio and solidifying its position as a leading pharmaceutical organization in India.

Commenting on the acquisition, **Nilesh Gupta, Managing Director, Lupin** said, “This acquisition aligns well with our strategic goal to broaden our presence in the Indian market. By offering a comprehensive range of products, our aim is to deliver even greater value to our stakeholders and the communities we serve.”

“Growing urbanization and dietary changes are driving the demand for gastrointestinal and urology treatments in India,” said **Rajeev Sibal, President – India Region Formulations, Lupin**. “This acquisition strengthens our presence in India and bolsters our therapy pipeline. At Lupin, we are committed to empowering healthcare professionals in managing the increasing disease burden and improving the lives of patients significantly.”

“Lupin has been successfully marketing the scope brands for Menarini since 2021, which has been a testament to our evolved collaboration. I am happy that Lupin will now carry forward their legacy with full trademark ownership. For Menarini, this transaction further signals our continued commitment to nurture and expand our Dermatology and Aesthetics portfolio and business. Menarini is a top 10 multi-national company in this therapeutic area in India and has witnessed strong organic and inorganic growth,” said **Girisan Kariangal, Managing Director – Menarini India**.

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on:

Twitter: <https://twitter.com/LupinGlobal>

LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

About Menarini

The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over \$4.4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini's products are available in 140 countries worldwide. For further information, please visit www.menarini.com. Menarini India is a 100% subsidiary of the Menarini group.

For further information or queries, please contact –

Shweta Munjal

Vice President and Head – Corporate Communications & Sustainability, Lupin

Email: shwetamunjal@lupin.com

Crystella Lim

Associate Director – Communications and Media, Menarini Asia-Pacific

Email: crystella.lim@menariniapac.com